| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Editorial board
|
|
Editorial board
|
page ii
|
|
|
In this issue
|
|
Miscellaneous
|
page xiii
|
|
|
Forthcoming papers
|
|
Miscellaneous
|
page xiv
|
|
|
EJC issue 11, 2005
|
|
News
|
pages 1495-1499
|
| Editorial Comment |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Confirmation of response in cancer clinical trials: A meaningless exercise?
In this issue of EJC, Perez-Gracia and colleagues question the need for confirmation of response reported in cancer clinical trials. To illustrate this problem, the authors have selected several phase...
|
P. Therasse,
E. Eisenhauer
|
Editorial
|
pages 1501-1502
|
| Reviews |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
The emerging family of hepatoblastoma tumours: From ontogenesis to oncogenesis
Abstract: The identification of distinct types and subtypes of hepatoblastoma has led to a successful classification of these lesions. In recent years, and particularly within large tumour trials, the...
|
Arthur Zimmermann
|
Full-length article
|
pages 1503-1514
|
|
|
Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer
Abstract: Insulin and insulin-like growth factors (IGFs) have critical functions in growth regulatory signalling pathways. They are part of a tightly controlled network of ligands, receptors, binding ...
|
Angelika M. Burger,
Brian Leyland-Jones,
Kris Banerjee,
Demetri D. Spyropoulos,
Arun K. Seth
et al.
|
Full-length article
|
pages 1515-1527
|
| Clinical Oncology |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Assessment of the value of confirming responses in clinical trials in oncology
Abstract: The requirement for a second assessment to confirm initial tumour response is required by all response guidelines. Its rationale, however, is not clear. We have conducted this study to compa...
|
Jose Luis Perez-Gracia,
Maria Muñoz,
Grant Williams,
Jun Wu,
Eva Carrasco,
Ignacio Garcia-Ribas,
Ana Peiro,
Jose Maria Lopez-Picazo,
Alfonso Gurpide,
Ana Chopitea,
Salvador Martín-Algarra,
Jesus García-Foncillas,
Johannes Blatter
et al.
|
Full-length article
|
pages 1528-1532
|
|
|
Standardised FDG uptake: A prognostic factor for inoperable non-small cell lung cancer
Abstract: The aim of this study was to investigate the relationship between standardised uptake value (SUV) obtained from [18F]fluorodeoxyglucose positron emission tomography (FDG PET) and treatment r...
|
Gerben R. Borst,
José S.A. Belderbos,
Ronald Boellaard,
Emile F.I. Comans,
Katrien De Jaeger,
Adriaan A. Lammertsma,
Joos V. Lebesque
et al.
|
Full-length article
|
pages 1533-1541
|
|
|
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)
Abstract: We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer. Ten patients (6.5%) developed cardiac event...
|
Matthew Ng,
David Cunningham,
Andrew R. Norman
|
Full-length article
|
pages 1542-1546
|
|
|
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer
Abstract: Rubitecan (RFS2000, 9 nitrocamptothecin,) is a new oral topoisomerase I inhibitor. We report a phase II, single-arm, open-label study of RFS2000 as first line treatment for non-small cell lu...
|
S. Baka,
M. Ranson,
P. Lorigan,
S. Danson,
K. Linton,
I. Hoogendam,
K. Mettinger,
N. Thatcher
et al.
|
Full-length article
|
pages 1547-1550
|
|
|
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer
Abstract: Longitudinal quality of life (QOL) assessment is infrequently made in adjuvant therapy for colorectal cancer (CRC). This analysis aims to assess QOL and quality adjusted survival (QAS) in pa...
|
Ian Chau,
Andrew R. Norman,
David Cunningham,
Tim Iveson,
Mark Hill,
Tamas Hickish,
Fiona Lofts,
Duncan Jodrell,
Andrew Webb,
Diana Tait,
Paul J. Ross,
Pat Shellito,
Jacqueline R. Oates
et al.
|
Full-length article
|
pages 1551-1559
|
|
|
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial
Abstract: This work was conducted to evaluate the effect of early intervention with epoetin alfa (EPO) on transfusion requirements, hemoglobin level (Hb), quality of life (QOL) and to explore a possib...
|
J.H. Savonije,
C.J. van Groeningen,
A. van Bochove,
A.H. Honkoop,
C.L. van Felius,
L.W. Wormhoudt,
G. Giaccone
et al.
|
Full-length article
|
pages 1560-1569
|
| Paediatric Oncology |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year peroid
Abstract: In the 1970s, survival rates after treatment for acute lymphoblastic leukaemia (ALL) in children and young adults (less than 25 years) in India were poor, even in specialised cancer centres....
|
I. Magrath,
V. Shanta,
S. Advani,
M. Adde,
L.S. Arya,
S. Banavali,
M. Bhargava,
K. Bhatia,
M. Gutiérrez,
D. Liewehr,
S. Pai,
T.G. Sagar,
D. Venzon
et al.
|
Full-length article
|
pages 1570-1583
|
|
|
Strategies to improve outcomes of children with cancer in low-income countries
The feasibility of curing children with cancer has been demonstrated primarily in resource-rich countries. The 80% cure rate for childhood acute lymphoblastic leukemia (ALL) in these developed countri...
|
Scott C. Howard,
Raul C. Ribeiro,
Ching-Hon Pui
|
Discussion
|
pages 1584-1587
|
|
|
Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy
Abstract: High-dose methotrexate (HDMTX) is used increasingly to treat children with central nervous system (CNS) tumours. Although the neuro-imaging features of leukoencephalopathy associated with sy...
|
Stewart J. Kellie,
Jyoti Chaku,
Liane R. Lockwood,
Peter O’Regan,
Keith D. Waters,
Christopher K.F. Wong,
on behalf of the Australian and New Zealand Children’s Haematology Oncology Group
et al.
|
Full-length article
|
pages 1588-1596
|
| Epidemiology and Cancer Prevention |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations
Abstract: We present five families of paediatric patients suffering from choroid plexus carcinoma in which we found germline TP53 mutations. Only one of the families conformed to the criteria of Li–Fr...
|
Vera Krutilkova,
Marie Trkova,
Julie Fleitz,
Vladimir Gregor,
Kamila Novotna,
Anna Krepelova,
David Sumerauer,
Roman Kodet,
Simona Siruckova,
Pavlina Plevova,
Sarka Bendova,
Petra Hedvicakova,
Nicholas K. Foreman,
Zdenek Sedlacek
et al.
|
Full-length article
|
pages 1597-1603
|
|
|
Population-based survival of children in New Zealand diagnosed with cancer during 1990–1993
Abstract: In this study, we have aimed to characterise the survival of all 0–14 year-old New Zealand children who were diagnosed with cancer during 1990–1993. Four hundred and nine children were follo...
|
N.M. Douglas,
J.D. Dockerty
|
Full-length article
|
pages 1604-1609
|
|
|
Hereditary breast cancer growth rates and its impact on screening policy
Abstract: Imaging is often performed yearly for the surveillance of BRCA1/2 mutation carriers and women at high familial breast cancer risk. Growth of cancers in carriers may be faster as these tumour...
|
Madeleine M.A. Tilanus-Linthorst,
Mieke Kriege,
Carla Boetes,
Wim C.J. Hop,
Inge-Marie Obdeijn,
Jan C. Oosterwijk,
Hans L. Peterse,
Harmine M. Zonderland,
Sybren Meijer,
Alexander M.M. Eggermont,
Harry J. de Koning,
Jan G.M. Klijn,
Cecile T.M. Brekelmans
et al.
|
Full-length article
|
pages 1610-1617
|
| Experimental Oncology |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells
Abstract: mRNA-based technologies and preclinical research in a variety of animal models have shown that guanylyl cyclase C (GCC) is a highly sensitive and specific molecular marker for the diagnosis ...
|
E. Buc,
M. Der Vartanian,
C. Darcha,
P. Déchelotte,
D. Pezet
et al.
|
Full-length article
|
pages 1618-1627
|
|
|
Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes
Abstract: Purpose: The tuberous sclerosis (TSC) genes TSC1 and TSC2 encode the protein products hamartin and tuberin, respectively, and are putative tumour suppressor genes. Germ-line mutation of eith...
|
Wen G. Jiang,
Julian Sampson,
Tracey A. Martin,
Lisa Lee-Jones,
Gareth Watkins,
Anthony Douglas-Jones,
Kefah Mokbel,
Robert E. Mansel
et al.
|
Full-length article
|
pages 1628-1636
|
|
|
The mechanism of action of Kahalalide F: Variable cell permeability in human hepatoma cell lines
Abstract: Kahalalide F (KF) is a small natural peptide that showed activity in vitro and in vivo. The dose-limiting toxicity in clinical trials was transaminitis. We investigated the cytotoxicity of K...
|
J.M. Sewell,
I. Mayer,
S.P. Langdon,
J.F. Smyth,
D.I. Jodrell,
S.M. Guichard
et al.
|
Full-length article
|
pages 1637-1644
|
|
|
Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma
Abstract: The expression of cyclooxygenase 2 (COX-2) protein is increased in many tumours and may be associated with a more aggressive phenotype. We aimed to assess COX-2 expression in a large series ...
|
S.L. O’Kane,
L. Cawkwell,
A. Campbell,
M.J. Lind
|
Full-length article
|
pages 1645-1648
|
|
|
The prevalence of PIK3CA mutations in gastric and colon cancer
Abstract: A wide variety of tumours show PIK3CA mutations leading to increased phosphatidylinositol-3 kinase (PI3K) activity. We have determined the frequency of PIK3CA mutations in exons 9 and 20 tha...
|
Sérgia Velho,
Carla Oliveira,
Ana Ferreira,
António Carlos Ferreira,
Gianpaolo Suriano,
Simó Schwartz,
Alex Duval,
Fátima Carneiro,
José Carlos Machado,
Richard Hamelin,
Raquel Seruca
et al.
|
Full-length article
|
pages 1649-1654
|
| Letters |
| |
Article Title |
Author(s) |
Type |
Pages |
|
|
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations
I read with interest the article by Martoni and colleagues that reported the clinical and pharmacoeconomic findings of a randomised controlled trial of cisplatin plus vinorelbine or gemcitabine in pa...
|
Dyfrig A. Hughes
|
Correspondence
|
page 1655
|
|
|
Reply to the Letter to the Editor by Hughes in response to the article entitled “Multicentre randomised Phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced NSCLC”, published in vol. 41 Issue 1 of the European Journal of Cancer
It is the result of direct observation, and not of inference, that cisplatin plus vinorelbine (CP+VNR) was cheaper overall compared to cisplatin plus gemcitabine (CP+GEM), in the perspective of our ho...
|
Andrea Martoni,
Lorenzo Mantovani
|
Correspondence
|
pages 1656-1657
|
|
|
Calendar
|
|
Calendar
|
pages I-II
|
